Phase 2 trial data of a COVID-19 vaccine developed by Medigen Vaccine Biologics Corp (高端疫苗) looked promising, but professional review is needed to assess the vaccine’s efficacy, Minister of Health and Welfare Chen Shih-chung (陳時中) said at a news briefing at the Central Epidemic Command Center yesterday.
Medigen announced the results of the vaccine trial on Thursday afternoon, following the Food and Drug Administration’s (FDA) announcement of emergency use authorization standards for locally developed vaccines earlier that day.
Despite Medigen’s optimistic outlook, questions have been raised whether the successful phase 2 trial is enough to determine whether the vaccine offers adequate protection
There must be caution in the distribution of COVID-19 vaccines developed by Medigen Vaccine Biologics Corp and United Biomedical Inc before their phase 3 trials are conducted, former Centers for Disease Control director Su Ih-jen (蘇益仁) said on Monday.
Su’s comment came a day after Chinese-language media reported that Academia Sinica research fellow Chen Pei-jer (陳培哲) quit a Food and Drug Administration advisory committee to protest the government’s vaccine authorization plans.
Chen said he resigned late last month because he felt that the committee would have trouble remaining neutral when reviewing domestic vaccine candidates, with the major challenge to neutrality posed by
Taiwan's Medigen Vaccine Biologics Corp said on Thursday that it was seeking a speedy emergency use authorisation, or EUA, from the government for its COVID-19 vaccine candidate after safely completing phase II trials.
Taipei, June 10 (CNA) Medigen Vaccine Biologics Corp., a Taiwan-based biopharmaceutical company, said Thursday that it would seek an Emergency Use Authorization (EUA) for its COVID-19 vaccine candidate after successfully completing Phase II clinical trials.
Taipei, June 9 (CNA) Medigen Vaccine Biologics Corp., a Taiwan-based biopharmaceutical company, said Wednesday it is ready to present the data from the Phase II clinical trials of its COVID-19 vaccine candidate.